Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 5, 2025
Daily News
March 5, 2025
- Japan’s FY2025 Draft Budget Clears Lower House
March 5, 2025
- Unexpected Demand Triggers Supply Curb for Eisai’s ALS Med Just 3 Months after Launch; Patients Urge Early Response
March 5, 2025
- Meiji Invests in French Vaccine Player Osivax
March 5, 2025
- Sumitomo Group Continues to Seek Best Partners for Pharma Biz
March 5, 2025
- Protagonist/Takeda’s Hematology Med Makes Mark in PIII
March 5, 2025
- Sato, Eisai to Wind Up Collab on Antifungal Nailin
March 5, 2025
- Nippon Kayaku Files Nuvation-Partnered ROS1 Inhibitor in Japan
March 5, 2025
- Enhertu Hits OS Goal in 2nd-Line Gastric Cancer Use
March 5, 2025
- Japan Pharma Market Hits 11.5 Trillion Yen in 2024, Keytruda Wins Crown: IQVIA
March 5, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…